5HT2A Agonist–Modulator Therapy for Hallucinogenic Effect Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with the 5HT2A receptor, such as psychiatric disorders and neurodegenerative diseases, are inadequate in managing hallucinogenic effects and other symptoms, and there is a need for more effective therapeutic approaches.
Innovation Solution
Compositions and methods involving the administration of 5HT2A receptor agonists in conjunction with modulator compounds, such as alpha7 nicotinic acetylcholine receptor modulators, to modulate the subject's response to the agonists, thereby treating or ameliorating conditions like schizophrenia, depression, and anxiety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 5HT2A receptor agonists are administered to treat psychiatric disorders and neurodegenerative diseases, then therapeutic effects are achieved, but hallucinogenic effects occur as adverse side effects
Solution Approach 1:
The patent employs modulator compounds as intermediary substances that bridge the therapeutic agonist and the receptor target. These modulators fine-tune the agonist-receptor interaction, enhancing therapeutic effects while filtering out harmful hallucinogenic effects. The modulator acts as a control mechanism that regulates the intensity and specificity of 5HT2A receptor activation.
Solution Approach 2:
The patent utilizes parameter changes by administering modulator compounds that alter the pharmacological parameters of 5HT2A receptor agonists. The modulators change the binding affinity, efficacy, or selectivity parameters of the agonist, thereby transforming the overall effect profile from one that produces hallucinations to one that provides targeted therapeutic benefits without adverse effects.
2Adaptability or versatility
If current treatments are used for 5HT2A receptor-mediated conditions, then some therapeutic coverage is provided, but the treatments are inadequate in managing hallucinogenic effects and other symptoms
Solution Approach 1:
The patent applies the composite materials principle by combining two pharmacological agents: a 5HT2A receptor agonist and a modulator compound. This composite therapeutic approach creates a synergistic effect where the agonist provides broad therapeutic coverage for various psychiatric and neurodegenerative conditions, while the modulator compound refines and optimizes the treatment by specifically managing hallucinogenic effects and other symptoms that the agonist alone cannot control.
Data Source
AI summary
Provided herein, inter alia, methods of treating or ameliorating a 5HT2A mediated condition in a subject, compositions (e.g., pharmaceutical compositions), and kits for use in treating or ameliorating a 5HT2A mediated condition in a subject.